- Previous Close
4.1000 - Open
3.8000 - Bid 4.0000 x 255900
- Ask 4.1000 x 42900
- Day's Range
3.6000 - 4.7000 - 52 Week Range
3.6000 - 36.5000 - Volume
57,312,660 - Avg. Volume
5,340,010 - Market Cap (intraday)
73.91M - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date Feb 4, 2025 - Feb 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
www.biolinerx.comRecent News: BLRX.TA
View MorePerformance Overview: BLRX.TA
Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BLRX.TA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BLRX.TA
View MoreValuation Measures
Market Cap
81.90M
Enterprise Value
83.50M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.58
Price/Book (mrq)
2.63
Enterprise Value/Revenue
1.05
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-176.67%
Return on Assets (ttm)
-35.23%
Return on Equity (ttm)
-171.94%
Revenue (ttm)
17.05M
Net Income Avi to Common (ttm)
-30.12M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
40.06M
Total Debt/Equity (mrq)
223.55%
Levered Free Cash Flow (ttm)
-15.81M